Sponsored by AbbVie Medical Affairs
Janet Pope Janetbirdope
3 months 2 weeks ago
3 facts in #lupus to make you think 🤔
💧biomarkers in #SLE blood & #urine May predict #activity
OP0255
#Membranous #nephritis is serious in SLE @ZahiTouma POS0732
#prednisone dose irrelevant for #damage if in LLDAS -no diff between 7.5mg vs 5mg OP0124
#EULAR2024 @RheumNow
Janet Pope Janetbirdope
3 months 2 weeks ago
#Hope for patients with #active #SLE
The next hurdle is getting through
▶️Phase3 #RCTs
And
▶️Obtaining drug reimbursement so patients can get access to effective
#lupus #Rx
#EULAR2024
@RheumNow @eular_org https://t.co/sGzQXO4A2r
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
OP0072 @RheumNow #EULAR2024
Effects of #Upadacitinib or #Adalimumab on pain in #RA
SELECT-COMPARE Phase 3 study
UPA & ADA led to improvements in pain vs PBO
PtGA & TJC28 pain improvement similar between UPA & ADA
➡️ UPA may be more effective in control of pain than ADA in RA
Dr. Antoni Chan synovialjoints
3 months 2 weeks ago
Can we prevent psoriatic arthritis? Highlights from #EULAR2024 that help us understand this topic better @RheumNow https://t.co/E8Wy8FH4oU
Janet Pope Janetbirdope
3 months 2 weeks ago
#Vaccinations against #herpes #zoster in #MTX +#Upadacitinib Pts
▶️ #Shingrix works
👍Pts followed to 60 months
#EULAR2024
@eular_org @RheumNow
#OP0020 https://t.co/8ORC3Nd2FK
Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few presentations on this topic that will help us understand this progression from PsO to PsA better.
Several abstracts are presenting new compounds, targeting either RA well-known inflammatory pathways or offering new mechanisms of action or therapeutic sequences; these are summarized below.
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
OP0018 @RheumNow #EULAR2024
🔎 Study looked at early RA patient trajectories through time-independent disease state
📊 Authors demonstrated 4⃣ trajectories in early RA
🦴 Inflammation in joints, blood & poor response are main discriminatory factors https://t.co/IeDIU3jg9B
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
➡️ OP0064 @RheumNow #EULAR2024
➡️ Non-articular pain (NAP) at early RA diagnosis & evolution over the first yr of RA treatment
➡️ NAP, esp regional NAP, common in early RA during 1st yr
➡️ NAP in axial, both upper quadrants and both lower quadrants common https://t.co/FOGcS05Z25
Mrinalini Dey DrMiniDey
3 months 2 weeks ago
OP0086 #EULAR2024 @RheumNow #EULARBest
Pain & remission/low disease activity at 3m in pts with #RA in RA-BE-REAL
Pts taking #baricitinib more likely to achieve pain control vs TNFi/other mode of action
1/2 pts achieving remission/LDA & had bari achieved ≥70% pain relief.